Compare BCYC & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCYC | LAB |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.8M | 270.6M |
| IPO Year | 2019 | 2008 |
| Metric | BCYC | LAB |
|---|---|---|
| Price | $3.52 | $0.61 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | 483.4K | ★ 785.3K |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.33 | $0.62 |
| 52 Week High | $9.08 | $1.72 |
| Indicator | BCYC | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 34.13 |
| Support Level | $3.33 | N/A |
| Resistance Level | $3.99 | $0.79 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 18.70 | 3.28 |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.